[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100271815":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":40,"collaborators":42,"id":48,"slug":7,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":7,"maxAge":7,"enrollmentInfo":56,"targetDuration":59,"studyType":60,"phases":7,"briefSummary":61,"conditions":62,"keywords":72,"overallStatus":23,"whyStopped":7,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Joshua Brandstadter, MD, PhD, MSc","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","267-847-8220","joshua.brandstadter@pennmedicine.upenn.edu",{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},"Bridget Austin, MSc","2675869977","accelerate@uphs.upenn.edu",[22],{"facility":5,"status":23,"city":24,"state":25,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Philadelphia","Pennsylvania","19104","United States",{"type":29,"coordinates":30},"Point",[31,32],-75.16362,39.95238,{"lat":32,"lon":31},[35,36,38],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"name":18,"role":14,"phone":37,"phoneExt":7,"email":20},"267-586-9977",{"name":39,"role":11,"phone":7,"phoneExt":7,"email":7},"Joshua C Brandstadter, MD, PhD, MSc",{"type":41,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[43,46],{"name":44,"class":45},"EUSA Pharma, Inc.","INDUSTRY",{"name":47,"class":6},"Castleman Disease Collaborative Network","100271815",false,"NCT02817997","International Registry for Patients With Castleman Disease","ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment\u002FEffectiveness Research): An International Registry for Patients With Castleman Disease","ACCELERATE","Inclusion Criteria:\n\n* Person of any age\n* Have a reference pathology report suggesting \"Castleman disease\" not limited to cutaneous involvement only that can be uploaded\n* Be able to provide electronic informed consent, as per local regulations\n* Deceased patients may also be enrolled when a reference pathology report suggesting \"Castleman disease\" can be supplied or when the ART is able to locate and upload such a pathology report.\n\nExclusion Criteria:\n\n* Because this registry is designed to provide as wide a picture of routine clinical practice as possible, inclusion criteria are set deliberately wide and there are no exclusion criteria.","ALL",{"count":57,"type":58},1000,"ESTIMATED","10 Years","OBSERVATIONAL","The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.",[63,64,65,66,67,68,69,70,71],"Castleman Disease","Castleman's Disease","Giant Lymph Node Hyperplasia","Angiofollicular Lymph Hyperplasia","Angiofollicular Lymph Node Hyperplasia","Angiofollicular Lymphoid Hyperplasia","GLNH","Hyperplasia, Giant Lymph Node","Lymph Node Hyperplasia, Giant",[73,74,75,76,77,78,64,66,79,80],"patient registry","ACCELERATE study","CD","MCD","iMCD","Castleman","multicentric Castleman's disease","multicentric Castleman disease","2026-02-27",{"date":83,"type":84},"2026-03-03","ACTUAL",{"date":86,"type":7},"2016-10",{"date":88,"type":58},"2027-09",{"name":5,"class":6},1]